GM16726
LCL from B-Lymphocyte
Description:
LYMPHOBLASTIC LEUKEMIA, ACUTE, WITH LYMPHOMATOUS FEATURES; LALL
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
dbGaP |
| Class |
Heritable Cancer Syndromes and other Cancers |
|
Biopsy Source
|
Peripheral vein
|
|
Cell Type
|
B-Lymphocyte
|
|
Tissue Type
|
Blood
|
|
Transformant
|
Epstein-Barr Virus
|
|
Sample Source
|
LCL from B-Lymphocyte
|
|
Race
|
Black/African American
|
|
Family Member
|
1
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Karyotypic analysis after cell line submission to CCR
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase,Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
| |
| Cytogenetics |
Chromosome 13: DELETION Aneuploid Segment (-)13q12>13q14 |
|
Chromosome 9: TRANSLOCATION Breakpoint 9p24 t(8;9)9p24 |
| Remarks |
Line KLC; was established in 1992 from a patient in leukemic phase of B-cell lymphoma. His WBC count was 183,000/mm3 and 67% blast cells. The blast cells were positive for HLA-DR, CD19, CD20, and CD21, but were negative for myeloid markers, indicating that the cells are pre-B-lymphoid cells. The sub-cell line, KLC-HSV2 (GM16727), was derived from KLC cell line infected with Herpes Simplex Virus Type II (HSV-2) in January of 1994. |
| Herrera L, Santos S, Vesga MA, Anguita J, Martin-Ruiz I, Carrascosa T, Juan M, Eguizabal C, Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells Scientific reports9:18729 2019 |
| PubMed ID: 31822751 |
| |
| Kao YS, Sundin DR, Gebhardt BM, Persistent infection of a lymphoma cell line by herpes simplex virus. Am J Hematol62(2):93-8 1999 |
| PubMed ID: 10509003 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not Inactivated |
| Substrate |
None specified |
| Subcultivation Method |
dilution - add fresh medium |
| Supplement |
- |
|
|